爵士製藥 JAZZ 深 滬
交易中 09-19 12:55:40 美东时间
112.81
+3.245
+2.96%
華盛通- 最 高113.30
- 今 開110.30
- 成交量 44.41万股
- 最 低 109.60
- 昨 收 109.565
- 總市值 70.33亿
- 52周最高 137.385
- 市盈率 靜 18.49
- 換手率 0.71%
- 52周最低 99.06
- 委 比 34.48%
- 總股本 6234.53万
- 歷史最高 194.73
- 量 比 1.56
- 振 幅 3.38%
- 歷史最低 31.87
- 每 手 1
- 風險率 8.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Stock moves reflect downgrade for US economic growth outlook - Goldman
Equity rotations recently are reflecting a downgrade for the growth outlook on the US economy, but the S&P 500 (SP500) remains near its all-time high because of anticipated interest-rate cuts by the F...
09-16 03:48
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $140 Price Target
Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $140 price target.
09-09 23:43
50 stocks to invest during the bull steepening – Part 2
Stifel analysts believe that the most likely scenario during the second half of the year is a “bull steepening,” when the 2-year yield (US2Y) falls more than the 10-year yield (US10Y). “Investors thin...
09-06 01:38
Jazz Pharmaceuticals prices $850M senior notes
Jazz Pharmaceuticals (NASDAQ:JAZZ) priced $850M aggregate principal amount of 3.125% exchangeable senior notes due 2030 in a private offering by its subsidiary Jazz Investments I. The issuer also gran...
09-04 18:17
快讯 | 爵士制药股票下跌4%，在850万美元可换股债务交易计划后
Jazz Pharmaceuticals Shares Down 4% After $850 Mln Convertible Debt Deal Plans
09-03 21:59
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and claim the company raised Xyrem's price by over 800%.
08-29 01:37
快讯 | avadel pharmaceuticals：特拉华州地方法院驳回了爵士制药公司对禁止令的永久请求，禁止该公司的子公司销售lumryz。
Avadel Pharmaceuticals: Delaware District Court Denied Request by Jazz Pharma o...
08-28 19:05
Exploring The Competitive Space: Eli Lilly Versus Industry Peers In Pharmaceuticals
In today's rapidly changing and highly competitive business world, it is impera...
08-23 23:00
Jazz Pharma Epidyolex phase 3 trial fails in Japan
A phase 3 trial of Jazz Pharmaceuticals' (NASDAQ:JAZZ) Epidyolex (cannabidiol) failed in a Japanese study examining the drug to treat seizures associated with several conditions in pediatric patients....
08-23 05:03
快讯 | 爵士制药股份有限公司 - 试验未达到主要疗效终点
Jazz Pharmaceuticals PLC - Trial Did Not Meet Primary Efficacy Endpoint
08-23 04:05
